|
1
|
Kaira K, Tomizawa Y, Imai H, Sakurai R,
Matsuura M, Yoshii A, Ochiai M, Kotake M, Ebara T, Saitoh JI, et
al: Phase I study of nab-paclitaxel plus carboplatin and concurrent
thoracic radiotherapy in patients with locally advanced non-small
cell lung cancer. Cancer Chemother Pharmacol. 79:165–171. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Dong Z, Zhao L, Lu S, Xiong J and Geng Z:
Overexpression of TSPAN8 promotes tumor cell viability and
proliferation in nonsmall cell lung cancer. Cancer Biother
Radiopharm. 31:353–359. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Presley CJ, Soulos PR, Tinetti M, Montori
VM, Yu JB and Gross CP: Treatment burden of medicare beneficiaries
with stage I non-small-cell lung cancer. J Oncol Pract.
13:e98–e107. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Qiu ZL, Shen CT, Sun ZK, Wei WJ, Zhang XY,
Song HJ and Luo QY: Circulating long non-coding rnas act as
biomarkers for predicting 131I uptake and mortality in papillary
thyroid cancer patients with lung metastases. Cell Physiol Biochem.
40:1377–1390. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Liu TC, Hsieh MJ, Wu WJ, Chou YE, Chiang
WL, Yang SF, Su SC and Tsao TC: Association between survivin
genetic polymorphisms and epidermal growth factor receptor mutation
in non-small-cell lung cancer. Int J Med Sci. 13:929–935. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ma L, Qiu B, Zhang J, Li QW, Wang B, Zhang
XH, Qiang MY, Chen ZL, Guo SP and Liu H: Survival and prognostic
factors of non-small cell lung cancer patients with postoperative
locoregional recurrence treated with radical radiotherapy. Chin J
Cancer. 36:932017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wei WE, Mao NQ, Ning SF, Li JL, Liu HZ,
Xie T, Zhong JH, Feng Y, Wei CH and Zhang LT: An analysis of EGFR
mutations among 1506 cases of non-small cell lung cancer patients
in Guangxi, China. PLoS One. 11:e01687952016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ghafoor Q, Baijal S, Taniere P, O'Sullivan
B, Evans M and Middleton G: Epidermal growth factor receptor (EGFR)
kinase inhibitors and non-small cell lung cancer (NSCLC)-advances
in molecular diagnostic techniques to facilitate targeted therapy.
Pathol Oncol Res. Dec 21–2017.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wang T, Xu X, Xu Q, Ren J, Shen S, Fan C
and Hou Y: miR-19a promotes colitis-associated colorectal cancer by
regulating tumor necrosis factor alpha-induced protein 3-NF-κB
feedback loops. Oncogene. 36:3240–3251. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Labourier E, Lloyd M, Andruss B, Adai A
and Schwarzbach A: An miRNA assay for the classification of benign
and neoplastic lesions in pancreatic fine-needle aspirates. J Clin
Oncol. 29 4 Suppl:S1632011. View Article : Google Scholar
|
|
11
|
Huang G, Pan J, Ye Z, Fang B, Cheng W and
Cao Z: Overexpression of miR-216b sensitizes NSCLC cells to
cisplatin-induced apoptosis by targeting c-Jun. Oncotarget.
8:104206–104215. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Pei K, Zhu JJ, Wang CE, Xie QL and Guo JY:
MicroRNA-185-5p modulates chemosensitivity of human non-small cell
lung cancer to cisplatin via targeting ABCC1. Eur Rev Med Pharmacol
Sci. 20:4697–4704. 2016.PubMed/NCBI
|
|
13
|
Sun CC, Li SJ, Zhang F, Zhang YD, Zuo ZY,
Xi YY, Wang L and Li DJ: The novel miR-9600 suppresses tumor
progression and promotes paclitaxel sensitivity in non-small-cell
lung cancer through altering STAT3 expression. Mol Ther Nucleic
Acids. 5:e3872016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang P, Deng Y and Fu X: MiR-509-5p
suppresses the proliferation, migration, and invasion of non-small
cell lung cancer by targeting YWHAG. Biochem Biophys Res Commun.
482:935–941. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wei Y, Sun J and Li X: MicroRNA-215
enhances invasion and migration by targeting retinoblastoma tumor
suppressor gene 1 in high-grade glioma. Biotechnol Lett.
39:197–205. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Li N, Zhang QY, Zou JL, Li ZW, Tian TT,
Dong B, Liu XJ, Ge S, Zhu Y, Gao J and Shen L: miR-215 promotes
malignant progression of gastric cancer by targeting RUNX1.
Oncotarget. 7:4817–4828. 2016.PubMed/NCBI
|
|
17
|
Li QW, Zhou T, Wang F, Jiang M, Liu CB,
Zhang KR, Zhou Q, Tian Z and Hu KW: MicroRNA-215 functions as a
tumor suppressor and directly targets ZEB2 in human pancreatic
cancer. Genet Mol Res. 14:16133–16145. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chen B, Huang Z, Zhang Y, Chen Y and Li Z:
MicroRNA-145 suppresses osteosarcoma metastasis via targeting
MMP16. Cell Physiol Biochem. 37:2183–2193. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Arslan D, Bozcuk H, Gunduz S, Tural D,
Tattli AM, Uysal M, Goksu SS, Bassorgun Cİ, Koral L, Coskun HS, et
al: Survival results and prognostic factors in T4 N0-3 non-small
cell lung cancer patients according to the AJCC 7th edition staging
system. Asian Pac J Cancer Prev. 15:2465–2472. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ahmad J, Baig MA, Ali AA, Al-Huqail A,
Ibrahim MM and Qureshi MI: Comparative assessment of four RNA
extraction methods and modification to obtain high-quality RNA from
Parthenium hysterophorus leaf. 3 Biotech. 7:3732017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Georges SA, Biery MC, Kim SY, Schelter JM,
Guo J, Chang AN, Jackson AL, Carleton MO, Linsley PS, Cleary MA and
Chau BN: Coordinated regulation of cell cycle transcripts by
p53-inducible microRNAs, miR-192 and miR-215. Cancer Res.
68:10105–10112. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang YX, Zhang TJ, Yang DQ, Yao DM, Yang
L, Zhou JD, Deng ZQ, Ma JC, Guo H, Wen XM, et al: Reduced miR-215
expression predicts poor prognosis in patients with acute myeloid
leukemia. Jpn J Clin Oncol. 46:350–356. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhou SW, Su BB, Zhou Y, Feng YQ, Guo Y,
Wang YX, Qi P and Xu S: Aberrant miR-215 expression is associated
with clinical outcome in breast cancer patients. Med Oncol.
31:2592014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chen Z, Han S, Huang W, Wu J, Liu Y, Cai
S, He Y, Wu S and Song W: MicroRNA-215 suppresses cell
proliferation, migration and invasion of colon cancer by repressing
Yin-Yang 1. Biochem Biophys Res Commun. 479:482–488. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hou Y, Zhen J, Xu X, Zhen K, Zhu B, Pan R
and Zhao C: miR-215 functions as a tumor suppressor and directly
targets ZEB2 in human non-small cell lung cancer. Oncol Lett.
10:1985–1992. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhang WL, Chen YF, Meng HZ, Du JJ, Luan
GN, Wang HQ, Yang MW and Luo ZJ: Role of miR-155 in the regulation
of MMP-16 expression in intervertebral disc degeneration. J Orthop
Res. 35:1323–1334. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Cao L, Chen C, Zhu H, Gu X, Deng D, Tian
X, Liu J and Xiao Q: MMP16 is a marker of poor prognosis in gastric
cancer promoting proliferation and invasion. Oncotarget.
7:51865–51874. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lin F, Wang X, Jie Z, Hong X, Li X, Wang M
and Yu Y: Inhibitory effects of miR-146b-5p on cell migration and
invasion of pancreatic cancer by targeting MMP16. J Huazhong Univ
Sci Technolog Med Sci. 31:509–514. 2011. View Article : Google Scholar : PubMed/NCBI
|
